Combination of External Beam Radiation (EBRT) with Intratumoral Injection of Dendritic Cells as Neo-Adjuvant Treatment of High-Risk Soft Tissue Sarcoma Patients

Before & After treatment

Before & after treatment



The aim of this study was to discover the effect of combination of dendritic cells (DC) and fractionated external beam radiation (EBRT) in patients with soft tissue sarcoma (STS). The results suggest the therapy is promising and resulted in induction of antitumor immune responses.

Patients characteristics

17 patients with histologically confirmed large Soft Tissue Sarcoma.


• Mononuclear cells for DC production were obtained after leukapheresis
• After thawing, cells were placed in X-VIVO-15 medium in tissue culture flasks at a concentration of 1.3 to 1.7×106 cells/cm2 of available culturing surface
• After 2 hours of culture, nonadherent cells were removed and the flask were recharged with X-VIVO-15 medium supplemented with 5ng/mL GMC- SF and 5ng/mL IL-4
• The flask was incubated for 48 hours at which time additional cytokine- supplemented medium was added to the flask, incubated for additional 72 hours
• After the completion of incubation, the nonadherent and loosely adherent
cells were collected and used for 2hour infection with Adp53 at a viral particle to all ration of 15,000:1.


Patients treated with EBRT combined with Intratumorally injection of DC. Radiation was delivered 5 days a week. DC 107 cells were injected IT 3 times on the 2nd, 3rd and 4th Friday during the course of radiation.


• No significant (>=grade2) toxicity was observed during combination of EBRT/DC treatment
• 12 patients (70.6%) had no evidence of the disease for at least 1 year after the start of the treatment.
• Among those 12, 6 patients are disease free for more than 2 years and 4 patients for more than 3 years.
• 9 out of 17 patients (52.9%) demonstrated a positive tumor-specific immune response which lasted from 11-42 weeks.


Combination of Intratumorally DC administration with EBRT was safe and resulted in induction of antitumor immune responses and could be a promising method for the treatment of patients with Soft Tissue Sarcoma (STS).

Article Reference link: click here

Scientific article publishing date: 11/23/2015

Immucura identifier BSC21_323EN